Reports Q2 revenue $23.7, consensus $22.86B. “Today’s strong results reflect the depth and strength of Johnson & Johnson’s uniquely diversified business operating across both MedTech and Innovative Medicine,” said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. “Our portfolio and pipeline position us for elevated growth in the second half of the year, with game-changing approvals and submissions anticipated in areas like lung and bladder cancer, major depressive disorder, psoriasis, surgery and cardiovascular, which will extend and improve lives in transformative ways.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Is Johnson & Johnson (JNJ) a Good Stock to Buy before Earnings?
- Notable companies reporting before tomorrow’s open
- Options Volatility and Implied Earnings Moves This Week, July 15 – July 18, 2025
- JNJ Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- FDA willing to trade faster drug reviews for lower prices, Bloomberg reports